Efficacy and Safety of Immune Checkpoint Inhibitors for Advanced Non-small Cell Lung Cancer with Leptomeningeal Metastases Harboring Targetable Mutations

Overview

Journal Transl Lung Cancer Res

Date 2024 Aug 9

PMID 39118876

Authors

Xiaoyu Ji

Rongrong Jiang

Tao Liu

Mariano Provencio

Sang Chul Lee

Qiong Zhan

Xinli Zhou

Affiliations

Soon will be listed here.

Abstract

Background: Driver gene-positive non-small cell lung cancer (NSCLC) patients are prone to develop leptomeningeal metastasis (LM), leading to an extremely high mortality. The objective of this study was to assess the efficacy and safety of immune checkpoint inhibitors (ICIs) treatments for patients with NSCLC and LM harboring targetable mutations.

Methods: We retrospectively collected records of patients with NSCLC harboring targetable mutations and prescribed ICIs following the diagnosis of LM at Huashan Hospital, Fudan University. In addition, we reviewed relevant literature and enrolled patients who met the inclusion criteria. Clinical characteristics were statistically analyzed, and the Kaplan-Meier method and log-rank test were employed to assess the median progression-free survival (mPFS) and median overall survival (mOS).

Results: A total of 37 patients with NSCLC harboring targetable mutations who received ICIs after LM diagnosis were included. The median age of the enrolled patients was 54 years (range, 33-70 years), and 62.2% were female. Following ICI administration, the intracranial objective response rate (iORR) and intracranial disease control rate (iDCR) for all enrolled patients were 18.9% and 62.2%, respectively. The mPFS of all patients was 2.5 months [95% confidence interval (CI): 2.166-2.834 months] and the mOS was 5.8 months (95% CI: 5.087-6.513 months). Both univariate and multivariate analyses revealed a significant increase in mOS or individuals who had previously undergone cranial radiation therapy compared to those who had not. Furthermore, different histology molecular types were found to be potentially associated with survival time.

Conclusions: Some patients with NSCLC harboring targetable gene mutations following LM diagnosis may benefit from ICI treatment with relatively good tolerance. However, further screening of the most suitable patient populations for ICIs is required.

References

Kaplan J, DeSouza T, Farkash A, Shafran B, Pack D, Rehman F . Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neurooncol. 1990; 9(3):225-9. DOI: 10.1007/BF02341153. View

Reck M, Mok T, Nishio M, Jotte R, Cappuzzo F, Orlandi F . Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med. 2019; 7(5):387-401. DOI: 10.1016/S2213-2600(19)30084-0. View

Brastianos P, Strickland M, Quant Lee E, Wang N, Cohen J, Chukwueke U . Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis. Nat Commun. 2021; 12(1):5954. PMC: 8511104. DOI: 10.1038/s41467-021-25859-y. View

Rabold K, Zoodsma M, Grondman I, Kuijpers Y, Bremmers M, Jaeger M . Reprogramming of myeloid cells and their progenitors in patients with non-medullary thyroid carcinoma. Nat Commun. 2022; 13(1):6149. PMC: 9579179. DOI: 10.1038/s41467-022-33907-4. View

Qian J, Yu J, Kluger H, Chiang V . Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery. Cancer. 2016; 122(19):3051-8. PMC: 5030143. DOI: 10.1002/cncr.30138. View

Brastianos P, Quant Lee E, Cohen J, Tolaney S, Lin N, Wang N . Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nat Med. 2020; 26(8):1280-1284. DOI: 10.1038/s41591-020-0918-0. View

Bernstein M, Krishnan S, Hodge J, Chang J . Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?. Nat Rev Clin Oncol. 2016; 13(8):516-24. PMC: 6053911. DOI: 10.1038/nrclinonc.2016.30. View

Lu S, Wu L, Jian H, Chen Y, Wang Q, Fang J . Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised,.... Lancet Oncol. 2022; 23(9):1167-1179. DOI: 10.1016/S1470-2045(22)00382-5. View

Le Rhun E, Devos P, Boulanger T, Smits M, Brandsma D, Ruda R . The RANO Leptomeningeal Metastasis Group proposal to assess response to treatment: lack of feasibility and clinical utility and a revised proposal. Neuro Oncol. 2019; 21(5):648-658. PMC: 6502503. DOI: 10.1093/neuonc/noz024. View

10.

Le Rhun E, Weller M, Brandsma D, van den Bent M, de Azambuja E, Henriksson R . EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. Ann Oncol. 2017; 28(suppl_4):iv84-iv99. DOI: 10.1093/annonc/mdx221. View

11.

Barbour A, Zaki P, McGranahan T, Venur V, Vellayappan B, Palmer J . Emergent radiotherapy for brain and leptomeningeal metastases: a narrative review. Ann Palliat Med. 2023; 12(6):1405-1419. DOI: 10.21037/apm-22-1276. View

12.

Tagliaferri L, Lancellotta V, Fionda B, Mangoni M, Casa C, Di Stefani A . Immunotherapy and radiotherapy in melanoma: a multidisciplinary comprehensive review. Hum Vaccin Immunother. 2021; 18(3):1903827. PMC: 9122308. DOI: 10.1080/21645515.2021.1903827. View

13.

Fan Y, Qin J, Han N, Lu H . HER2 exon 20 insertion mutations in lung adenocarcinoma with leptomeningeal metastasis: a case report and response to poziotinib. Ann Palliat Med. 2021; 11(4):1582-1588. DOI: 10.21037/apm-21-213. View

14.

Wen L, Zhen J, Shan C, Lai M, Hong W, Wang H . Efficacy and safety of osimertinib for leptomeningeal metastases from EGFR-mutant non-small cell lung cancer: a pooled analysis. Eur J Med Res. 2023; 28(1):267. PMC: 10403821. DOI: 10.1186/s40001-023-01219-y. View

15.

Zheng M, Li Y, Jiang B, Tu H, Tang W, Yang J . Clinical Utility of Cerebrospinal Fluid Cell-Free DNA as Liquid Biopsy for Leptomeningeal Metastases in ALK-Rearranged NSCLC. J Thorac Oncol. 2019; 14(5):924-932. DOI: 10.1016/j.jtho.2019.01.007. View

16.

Lee Y, Han J, Kim H, Yun T, Lee G, Kim H . Impact of EGFR tyrosine kinase inhibitors versus chemotherapy on the development of leptomeningeal metastasis in never smokers with advanced adenocarcinoma of the lung. J Neurooncol. 2013; 115(1):95-101. DOI: 10.1007/s11060-013-1199-y. View

17.

Yang Y, Wang Z, Fang J, Yu Q, Han B, Cang S . Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11). J Thorac Oncol. 2020; 15(10):1636-1646. DOI: 10.1016/j.jtho.2020.07.014. View

18.

Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot A, Mezquita L . Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019; 30(8):1321-1328. PMC: 7389252. DOI: 10.1093/annonc/mdz167. View

19.

Zheng M, Tu H, Yang J, Zhang X, Zhou Q, Xu C . Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments. Eur J Cancer. 2021; 150:23-30. DOI: 10.1016/j.ejca.2021.03.037. View

20.

Dudnik E, Yust-Katz S, Nechushtan H, Goldstein D, Zer A, Flex D . Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases. Lung Cancer. 2016; 98:114-117. DOI: 10.1016/j.lungcan.2016.05.031. View